Effect of aceclofenac on the human cartilage compared to other nonsteroidal anti-inflammatory drugs Review article
Article Sidebar
Published:
Dec 31, 2012
Keywords:
aceclofenac, nonsteroidal anti-inflammatory drug, human cartilage, chondrocyte, osteoarthritis
Main Article Content
Abstract
Interleukin 1 (IL-1), matrix metalloproteinases (MMP) and nitric oxide (NO) play a crucial role in the human cartilage degeneration in the course of osteoarthritis. The use of aceclofenac – selective cyclooxygenase 2 inhibitor (COX-2) with its own immunomodulatory activity – is essential not only for analgesic and anti-inflammatory aspect of the treatment. Chondroprotective properties of aceclofeanc were revealed in some in vitro studies.
Article Details
How to Cite
Rupiński , R. (2012). Effect of aceclofenac on the human cartilage compared to other nonsteroidal anti-inflammatory drugs. Medycyna Faktow (J EBM), 5(4(17), 23-27. Retrieved from https://www.journalsmededu.pl/index.php/jebm/article/view/2437
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Reumatologia kliniczna. Zimmerman-Górska I. (red.). PZWL, Warszawa 2008.
2. Reumatologia. Puszczewicz M. (red.). Medical Tribune Polska, Warszawa 2010.
3. Burmester G., Lanas A., Biasucci L. et al.: The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann. Rheum. Dis. 2011; 70: 818-822.
4. Legrand E.: Aceklofenak w leczeniu bólu związanego z zapaleniem. Expert Opin. Pharmacother. 2004; 5(6): 1347-1357.
5. Yamazaki R., Kawai S., Matsumoto T. et al.: Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cell. JPET 1999; 289: 676-681.
6. González E., de la Cruz C., de Nicoläs R. et al.: Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agent Actions 1994; 41: 171-178.
7. Dingle J.T., Parker M.: NSAID stimulation of human cartilage matrix synthesis. A study of the mechanism of action of aceclofenac. Clin. Drug Invest. 1997; 14: 353-362.
8. Henrotin Y., de Leval X., Mathy-Hartet M. et al.: In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm. Res. 2001; 50: 391-399.
9. Maneiro E., López-Armada M.J., Fernández-Sueiro J.L. et al.: Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes. J. Rheumatol. 2001; 28: 2692-2699.
10. Nietfeld J.J., Wilbrink B., Helle M. et al.: Interleukin-1-induced interleukin-6 is required for inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis Rheum. 1990; 33: 1695-1701.
11. Akimoto H., Yamazaki R., Hashimoto S. et al.: 4’-hydroxyaceclofenac supresses the interleukin-1-induced production of promatrix metalloproteinases and release of sulphated-glycosaminoglycans from rabbit articular chondrocytes. Eur. J. Pharmacol. 2000; 401: 429-436.
12. Blot L., Marcelis A., Devogelaer J.P., Manicourt D.H.: Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritis human cartilage. Br. J. Pharmacol. 2000; 131: 1413-1421.
13. Szałek E., Grześkowiak E.: Aceklofenak – NLPZ preferencyjnie hamujący cyklooksygenazę 2 o działaniu chondroprotekcyjnym. Geriatria 2012; 6: 135-142.
14. Fukai A., Kamekura S., Chikazu D. et al.: Lack of a chondroprotective effect of cyclooxygenase 2 inhibition in a surgically induced model of osteoarthritis in mice. Arthritis Rheum. 2012; 64: 198-203.
15. Alvarez-Soria M.A., Herrero-Beaumont G., Moreno-Rubio J. et al.: Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. Osteoarthritis Cartilage 2008; 16: 1484-1493.
2. Reumatologia. Puszczewicz M. (red.). Medical Tribune Polska, Warszawa 2010.
3. Burmester G., Lanas A., Biasucci L. et al.: The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann. Rheum. Dis. 2011; 70: 818-822.
4. Legrand E.: Aceklofenak w leczeniu bólu związanego z zapaleniem. Expert Opin. Pharmacother. 2004; 5(6): 1347-1357.
5. Yamazaki R., Kawai S., Matsumoto T. et al.: Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cell. JPET 1999; 289: 676-681.
6. González E., de la Cruz C., de Nicoläs R. et al.: Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agent Actions 1994; 41: 171-178.
7. Dingle J.T., Parker M.: NSAID stimulation of human cartilage matrix synthesis. A study of the mechanism of action of aceclofenac. Clin. Drug Invest. 1997; 14: 353-362.
8. Henrotin Y., de Leval X., Mathy-Hartet M. et al.: In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm. Res. 2001; 50: 391-399.
9. Maneiro E., López-Armada M.J., Fernández-Sueiro J.L. et al.: Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes. J. Rheumatol. 2001; 28: 2692-2699.
10. Nietfeld J.J., Wilbrink B., Helle M. et al.: Interleukin-1-induced interleukin-6 is required for inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis Rheum. 1990; 33: 1695-1701.
11. Akimoto H., Yamazaki R., Hashimoto S. et al.: 4’-hydroxyaceclofenac supresses the interleukin-1-induced production of promatrix metalloproteinases and release of sulphated-glycosaminoglycans from rabbit articular chondrocytes. Eur. J. Pharmacol. 2000; 401: 429-436.
12. Blot L., Marcelis A., Devogelaer J.P., Manicourt D.H.: Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritis human cartilage. Br. J. Pharmacol. 2000; 131: 1413-1421.
13. Szałek E., Grześkowiak E.: Aceklofenak – NLPZ preferencyjnie hamujący cyklooksygenazę 2 o działaniu chondroprotekcyjnym. Geriatria 2012; 6: 135-142.
14. Fukai A., Kamekura S., Chikazu D. et al.: Lack of a chondroprotective effect of cyclooxygenase 2 inhibition in a surgically induced model of osteoarthritis in mice. Arthritis Rheum. 2012; 64: 198-203.
15. Alvarez-Soria M.A., Herrero-Beaumont G., Moreno-Rubio J. et al.: Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. Osteoarthritis Cartilage 2008; 16: 1484-1493.